Ardelyx Faces Profit Challenges Despite Ibsrela Revenue Upside and New Pipeline Growth
Ardelyx’s Q4 results show a revenue beat but earnings miss, hurting stock despite a $1 billion 2029 goal for Ibsrela and new pipeline expansion.
3 minutes to read








